Ask where omega-3 comes from and most people say fish; ask about astaxanthin and those who know it at all say salmon or krill. Both answers name the messenger, not the author. Neither fish nor krill synthesise these molecules — marine microalgae do, and everything above them in the food chain merely accumulates what algae made. Modern supplement production increasingly skips the chain and cultivates the original producers directly. The logic deserves its own explanation, because it is one of the quiet revolutions in ingredient sourcing.
The food chain, inverted
In the ocean’s economy, microalgae are the primary producers: single-celled photosynthesisers that build EPA and DHA into their membranes and, in specific species, synthesise astaxanthin as a stress-protection pigment. Zooplankton eat algae; small fish eat zooplankton; salmon eat small fish — and at each step the algal molecules concentrate in fatty tissues, along with everything else the water contained. “Fish oil” is thus algal oil after several rounds of biological repackaging. Cultivating the algae directly is not a substitute for the natural source; it is the natural source, minus the intermediaries.
How cultivation actually works
Two production models dominate. Phototrophic cultivation grows algae on light and CO₂ — in open raceway ponds or, for higher-control applications, closed photobioreactors: transparent tube or panel systems where temperature, light, nutrients and sterility are managed and environmental contamination is excluded. Haematococcus pluvialis, the astaxanthin alga, uses a two-stage version: a green growth phase building biomass, then a deliberately stressful red phase (intense light, nutrient limitation) that triggers each cell to accumulate astaxanthin — the same stress response that reddens the organism in drying rock pools. Heterotrophic fermentation grows other species (notably Schizochytrium for DHA) in closed, sterile fermenters on a carbon substrate, pharma-style — no sunlight, total environmental control, remarkable oil yields. Extraction then recovers the goods: supercritical CO₂ or solvent extraction yielding an oleoresin (astaxanthin) or refined algal oil (EPA/DHA), followed by standardisation to declared potency.
The purity logic: skipping the chain skips its baggage
Every trophic step that concentrates omega-3 also concentrates the ocean’s persistent contaminants — methylmercury, PCBs, dioxins — which is why marine-oil quality control is largely a decontamination story, and why our CoA explainer puts heavy metals on every oil panel. Cultivated microalgae sit at the chain’s origin, grown in controlled water before any bioaccumulation occurs: contaminant burdens start near zero rather than being purified down. Three further consequences follow. No fish allergens — relevant for a meaningful allergic population. Vegan by nature — the only route to preformed EPA/DHA and natural astaxanthin without animal involvement. Batch consistency — cultivated biology under fixed conditions varies far less than wild catch by season and fishery. Independent batch testing remains non-negotiable — cultivation is a cleaner starting point, not a substitute for verification — but the analytical results explain why algal ingredients routinely test at the clean end of every contaminant table.
The sustainability dividend
The same inversion carries ecological weight: algal EPA/DHA production requires no fishing pressure on forage-fish stocks (the anchovy and sardine fisheries feeding the fish-oil industry), no bycatch, and a fraction of the land and freshwater footprint of terrestrial oil crops. As omega-3 demand grows against capped wild fisheries, cultivated algae are less an alternative than the category’s future capacity.
Reading the label: derived, oil, extract
Terminology on packaging follows the production reality. “Algal oil” / “algae oil”: the refined lipid fraction — the standard form for EPA/DHA, with the source species (e.g. Schizochytrium sp.) properly named in the ingredient list. “Extract” / “oleoresin”: a concentrated extract — the standard astaxanthin form, declared as Haematococcus pluvialis extract standardised to a stated astaxanthin percentage. “Algae-derived”: a truthful umbrella term that should always be backed, lower on the label, by the specific species and form. In the EU, these ingredients pass through Novel Food authorisation — Schizochytrium oil and H. pluvialis astaxanthin oleoresin hold authorisations with defined specifications — adding a regulatory identity layer to the biological one. A label naming species, form and standardisation is a label written by people who understand their own supply chain.
The clinical bottom line
Microalgae are not the alternative source of EPA, DHA and astaxanthin — they are the source, cultivated instead of fished. Direct cultivation delivers the identical molecules with near-zero contaminant inheritance, no allergens, vegan status, batch consistency and a fisheries-free footprint. On labels, look for the species name, the form (oil vs oleoresin), and standardised potency — the three words that separate supply-chain literacy from marketing.
Primary sources
- European Commission: Novel Food framework and Union list (algal oil, astaxanthin oleoresin authorisations)
- NIH ODS: Omega-3 fatty acids — sources incl. algal oils
- FAO: state of fisheries and the case for alternative omega-3 production
- GMJ: The global omega-3 shortfall
- GMJ: Astaxanthin’s membrane-spanning mechanism
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
